CD8A and glioblastoma: Prophylactic VEGF-C used in GBM models have demonstrated significant benefits, including enhanced lymphatic function, improved CD8+ T cell activation, and synergistic effects with immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 therapies 144, 145.